Revised Accutane Label Describes Lack Of PK Effect On Ortho-Novum
Roche has revised Accutane labeling to contain drug interaction information showing a lack of pharmacokinetic effect on Ortho-McNeil's oral contraceptive Ortho-Novum
You may also be interested in...
Celgene is in discussions with companies interested in licensing its patents covering the STEPS risk management program for Thalomid, President Sol Barer says July 22. Celgene holds five patents covering risk management programs that link patients, pharmacists and physicians through computerized databases. The patents are holding up implementation of revised risk management plans for isotretinoin (Roche's Accutane and generics) and could pose an obstacle to creation of a risk management program for Allergan's Tazoral (1"The Pink Sheet" July 19, 2004, p. 3)...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials